ReviewClinical medicine & research2020
Aspirin in Primary Prevention of Cardiovascular Events.
Review in Clinical medicine & research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pattern of use and awareness of side-effects of non-steroidal anti-inflammatory drugs among general public in Gondar city, North west Ethiopia.Scientific reports · 2026Article
- Article
- Antithrombotic Therapy in the Elderly with Cardiovascular Disease: Walking the Tightrope Between Efficacy and Bleeding Risk-A Narrative Review.Journal of clinical medicine · 2025Article
- The molecular mechanisms and therapeutic implications of PANoptosis in ischemic diseases.Apoptosis : an international journal on programmed cell death · 2025Review
- NOSH-aspirin (NBS-1120) attenuates motor defects and dopaminergic neuron degeneration in a rat model of Parkinson's disease.European journal of pharmacology · 2025Article
- Procoagulant effect of phosphatidylserine-exposed blood cells, endothelial cells and extracellular vesicles in patients with aortic stenosis.Thrombosis journal · 2025Article
- The Impact of pre-operative aspirin administration on free flap survival rate in lower extremity reconstructio n.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025Article
- The prevalence and factors associated with potentially inappropriate medications in Chinese older outpatients with heart failure.BMC geriatrics · 2024Article
- The pharmaco-epigenetics of hypertension: a focus on microRNA.Molecular and cellular biochemistry · 2024Review
- Anti-Platelet Activity of Sea Buckthorn Seeds and Its Relationship with Thermal Processing.Foods (Basel, Switzerland) · 2024Article
- Evolving Strategies for Use of Phytochemicals in Prevention and Long-Term Management of Cardiovascular Diseases (CVD).International journal of molecular sciences · 2024Review
- Genetic Evidence for Causal Relationships between Plasma Eicosanoid Levels and Cardiovascular Disease.Metabolites · 2024Article
- In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells.Current oncology (Toronto, Ont.) · 2023Article
- Meta-Analysis of Cardiovascular Risk Factors in Offspring of Preeclampsia Pregnancies.Diagnostics (Basel, Switzerland) · 2023Review
- Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects.Pharmaceutics · 2023Article
- Aspirin Inhibits Fibronectin Expression and Reverses Fibronectin-Mediated Cell Invasiveness by Activating Akt Signaling in Preeclampsia.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Author Response to "Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas".Clinical medicine & research · 2021Article
- Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas.Clinical medicine & research · 2021Article
- The limits of evidence-based medicine.Industrial psychiatry journalArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspirin has demonstrated a clear benefit in secondary prevention of coronary syndrome, while aspirin's effect in primary prevention is unclear. This report will explore the role of aspirin as primary prevention for various vascular events. It strives to provide a clear guide for clinicians on whether or not to prescribe aspirin for their patients for primary prevention. Current guidelines and recent trials failed to show clear benefit against primary prevention, with risks outweighing benefits in moderate to high risk patients. A thoughtful discussion between patients and their doctors should be conducted before beginning aspirin use. More studies are needed to gain a better understanding of aspirin use in primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.